Austedo vs Emgality
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Austedo | US Emgality | |
|---|---|---|
| Generic name | deutetrabenazine | galcanezumab |
| Drug class | VMAT2 Inhibitor | CGRP Antagonist (Biologic) |
| Treats | Tardive dyskinesia, Huntington's chorea | Migraine prevention, cluster headache |
| Category | Neurology | Neurology |
| Manufacturer | Teva | Eli Lilly |
| Year approved | 2017 | 2018 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $150M | $110M |
| Common side effects | Depression and suicidal thoughts (Huntington's), Drowsiness, Fatigue, Dry mouth | Injection site reactions, Constipation, Itching, Allergic reactions |
Frequently asked questions
Is Austedo or Emgality better?
Neither is universally "better." Austedo (deutetrabenazine) and Emgality (galcanezumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Austedo and Emgality?
Austedo is a VMAT2 Inhibitor made by Teva, while Emgality is a CGRP Antagonist (Biologic) made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Austedo has the larger estimated TV advertising budget of the two.